Halozyme Therapeutics Receivables

Halozyme Therapeutics (HALO) currently reports a receivables of $460M as of June 2026. That compares with $320M in the prior-year period — up 44.1% year over year. Use the charts on this page to explore Halozyme Therapeutics's receivables history and peer comparisons.

Halozyme Therapeutics's receivables increased from $320M to $460M — a 44.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Halozyme Therapeutics reported $460M in receivables as of June 2026. That compares with $320M in the prior-year period — up 44.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $460M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Halozyme Therapeutics, and consider following HALO for alerts when major investors trade the stock.

Halozyme Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $460M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HALO with unrelated industries.